Literature DB >> 29873906

S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations.

Alexander Nast1, Lasse Amelunxen2, Matthias Augustin3, Wolf-Henning Boehncke4, Corinna Dressler1, Matthew Gaskins1, Peter Härle5, Bernd Hoffstadt6, Joachim Klaus7, Joachim Koza7, Ulrich Mrowietz8, Hans-Michael Ockenfels9, Sandra Philipp10, Kristian Reich11, Thomas Rosenbach12, Berthold Rzany13, Martin Schlaeger14, Gerhard Schmid-Ott15, Michael Sebastian16, Ralph von Kiedrowski17, Tobias Weberschock18.   

Abstract

The German guideline for the treatment of psoriasis vulgaris was updated using GRADE methodology. The guideline is based on a systematic literature review completed on December 1, 2016, and on a formal consensus and approval process. The second part of this short version of the guideline covers the following special patient populations and treatment situations: tuberculosis screening before and during psoriasis treatment, choice of psoriasis treatment for individuals wishing to have children, as well as during pregnancy and breast-feeding, and patients with joint involvement and vaccinations. In addition, recommendations on the choice of treatment are presented for patients with the following comorbidities: hepatitis and other hepatic impairment, HIV, malignancies, neurological and psychiatric disorders, ischemic heart disease and congestive heart failure, diabetes mellitus, renal impairment and inflammatory bowel disease.
© 2018 The Authors | Journal compilation © Blackwell Verlag GmbH, Berlin.

Entities:  

Mesh:

Year:  2018        PMID: 29873906     DOI: 10.1111/ddg.13538

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN: 1610-0379            Impact factor:   5.584


  7 in total

1.  Prescription Behaviour and Barriers to Prescription of Biologicals for Treatment of Chronic Inflammatory Skin Diseases in Dermatological Practice in Two German Federal States.

Authors:  Daniela Weiss; Imke Nordhorn; Linda Tizek; Thomas Werfel; Alexander Zink; Tilo Biedermann; Stephan Traidl; Maximilian C Schielein
Journal:  Acta Derm Venereol       Date:  2021-09-28       Impact factor: 3.875

Review 2.  [Modern systemic therapies for atopic dermatitis : Which factors determine the choice of therapy?]

Authors:  Stephan Traidl; Annice Heratizadeh
Journal:  Dermatologie (Heidelb)       Date:  2022-06-01

3.  De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation.

Authors:  Panayotis Kaloyannidis; Eshrak Al Shaibani; Miral Mashhour; Mohammed Gamil; Ioannis Apostolidis; Hani Al Hashmi; Khalid Ahmed Al Anazi
Journal:  Case Rep Hematol       Date:  2018-10-16

Review 4.  Autoreactive T-Lymphocytes in Inflammatory Skin Diseases.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

5.  Analyzing the value of an educational program for psoriasis patients: a prospective controlled pilot study.

Authors:  Corinna Bubak; Marthe-Lisa Schaarschmidt; Lisa Schöben; Wiebke Katharina Peitsch; Astrid Schmieder
Journal:  BMC Public Health       Date:  2019-11-19       Impact factor: 3.295

6.  The impact of the first COVID-19 wave on office-based dermatological care in Germany: a focus on diagnosis, therapy and prescription of biologics

Authors:  Imke Nordhorn; Daniela Weiss; Thomas Werfel; Alexander Zink; Maximilian C Schielein; Stephan Traidl
Journal:  Eur J Dermatol       Date:  2022-04-01       Impact factor: 2.805

7.  Impact of Psoriasis on Mortality Rate and Outcome in Myocardial Infarction.

Authors:  Susanne Karbach; Lukas Hobohm; Johannes Wild; Thomas Münzel; Tommaso Gori; Joanna Wegner; Kerstin Steinbrink; Philip Wenzel; Karsten Keller
Journal:  J Am Heart Assoc       Date:  2020-09-11       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.